SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-023901
Filing Date
2022-11-09
Accepted
2022-11-09 16:22:16
Documents
64
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q antx-20220930.htm   iXBRL 10-Q 3342464
2 EX-10.1 antx-ex10_1.htm EX-10.1 44710
3 EX-31.1 antx-ex31_1.htm EX-31.1 21533
4 EX-31.2 antx-ex31_2.htm EX-31.2 21973
5 EX-32.1 antx-ex32_1.htm EX-32.1 13641
6 EX-32.2 antx-ex32_2.htm EX-32.2 13968
  Complete submission text file 0000950170-22-023901.txt   9637447

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT antx-20220930_pre.xml EX-101.PRE 308675
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT antx-20220930_def.xml EX-101.DEF 189636
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT antx-20220930_cal.xml EX-101.CAL 39294
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT antx-20220930.xsd EX-101.SCH 51804
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT antx-20220930_lab.xml EX-101.LAB 403960
58 EXTRACTED XBRL INSTANCE DOCUMENT antx-20220930_htm.xml XML 1607569
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41331 | Film No.: 221372985
SIC: 2834 Pharmaceutical Preparations